pravastatin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on tumour necrosis factor alpha concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Pravastatin use did not result in a significant change in CRP, LDL particle size, fasting triglycerides, Il-6, or TNF-α (Table 2).”
Quoted verbatim from A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.. - Study
- RCT
- Duration
- 3 months
- Dose
- 40 mg/day
- Population
- Outpatients aged 18 to 68 with schizophrenia or schizoaffective disorder on stable antipsychotic treatment; change from baseline to week 12 in the whole randomised sample
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.2014PMID:25261882Permalink
Keep reading
- Everything the graph holds on pravastatin
- Every compound studied against Tumour necrosis factor alpha concentration
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PR9FH72Z2F1K0245CZGB14